Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2026-04-22 Capital/Financing Update
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Capital/Financing Update Classification · 1% confidence The document is an SEC Form F-3 Registration Statement (shelf prospectus) dated April 21, 2026, detailing the resale of 23,333,333 ordinary shares issued in connection with a $21 million private placement convertible note. It is not an annual report, earnings release, or management change notice. It represents a capital‐raising and financing activity (the note issuance and registration of shares for resale). Thus, it best fits the “Capital/Financing Update” category (CAP).
2026-04-22 English
Other Report or Announcement
Report Publication Announcement Classification · 1% confidence The document is a brief notice under Regulation 5 of the Israeli Securities Regulations stating that a report (3-F) is attached as a PDF, without containing the report’s substantive content itself. It therefore qualifies as a report publication announcement rather than the report. Under the “menu vs. meal” rule (short announcement stating a report is attached), it should be classified as RPA.
2026-04-22 English
Immediate Report
Regulatory Filings
2026-04-21 Hebrew (modern)
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is an Immediate Report under Israeli Securities Regulations announcing that a Form 6-K report is attached (6k21042026_isa.pdf). It does not contain the full report content itself but simply notifies investors of its publication. This matches the definition of a Report Publication Announcement (RPA).
2026-04-21 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is a Form 6-K furnishing a press release by a foreign private issuer announcing the tokenization of its ordinary shares via Ondo Finance. It is not an earnings release, management discussion, capital raise, or regulatory requirement like insider trading or dividends. It is a general regulatory announcement/press release. As no more specific category applies, it falls under the fallback Regulatory Filings (RNS).
2026-04-08 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is an “Immediate Report” under Israeli Securities Authority rules, referencing form 6-K and noting “Attached hereto is a report on 6k…6k08042026_isa.pdf.” It does not contain the report itself but merely announces that the 6-K report is attached. Under the “menu vs meal” rule, this is an announcement of a report publication rather than the full report text. Therefore the correct classification is a Report Publication Announcement (RPA).
2026-04-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.